We provide a wide range of services including recombinant cell line development, bulk cell culture, assay design and optimization, and high content analysis (HCA).
The recent growth in cell use for drug discovery, particularly for high-throughput screening (HTS), has posed a number of challenges including batch performance variation, cell production scheduling, as well as capability and capacity management. In response, there has been a major increase in the acceptance of cryopreserved cells for use in drug discovery research. This offers the potential for single batches of cells to be produced in quantities sufficient for complete screening campaigns and effectively decouples cell production from screening.
Customized bulk cell production decouples cell production from screening
We offer reliable stem cell-derived analysis tools for drug discovery research. Cytiva Cardiomyocytes are derived from human embryonic stem (hES) cells and provide a biologically relevant alternative to current cell models and primary cells for predictive toxicity testing.